Products
Olmesafe-AM 5/20 & 5/40
Generic
Name
Amlodipine Besilate BP & Olmesartan Medoxomil BP
Preparation
Olmesafe-AM 5/20 Tablet: Each film coated tablet contains Amlodipine Besilate BP equivalent to Amlodipine 5 mg and Olmesartan Medoxomil BP 20 mg.
Olmesafe-AM 5/40 Tablet: Each film coated tablet contains Amlodipine Besilate BP equivalent to Amlodipine 5 mg and Olmesartan Medoxomil BP 40 mg.
Olmesafe-AM 5/40 Tablet: Each film coated tablet contains Amlodipine Besilate BP equivalent to Amlodipine 5 mg and Olmesartan Medoxomil BP 40 mg.
Therapeutic
Class
Angiotensin Receptor Blockers & Calcium channel blocker
Indications
Treatment of essential hypertension. Olmesafe-AM is indicated in adult patients whose blood pressure is not adequately controlled on Olmesartan Medoxomil or Amlodipine monotherapy.
Dosage & Administration
Adults: The recommended dosage of Olmesartan Medoxomil and Amlodipine is one tablet per day. Olmesafe-AM may be administered in patients whose blood pressure is not adequately controlled by 40 mg Olmesartan Medoxomil or 5 mg Amlodipine alone. Olmesafe-AM can be taken with or without food.
Elderly (age 65 years or over): No adjustment of the recommended dose is generally required for older people but increase of the dosage should take place with care. If up-titration to the maximum dose of 40 mg Olmesartan Medoxomil daily is required, blood pressure should be closely monitored.
Contraindications
Hypersensitivity to the active substances, to dihydropyridine derivatives or to any of the excipients, severe hepatic insufficiency and biliary obstruction.
Overdosage
There is no experience of overdose with Olmesartan Medoxomil and Amlodipine. The most likely effects of Olmesartan Medoxomil overdosage are hypotension and tachycardia; bradycardia could be encountered if parasympathetic (vagal) stimulation occurred. Amlodipine overdosage can be expected to lead to excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia.